<DOC>
	<DOC>NCT01435434</DOC>
	<brief_summary>The study is a prospective, trial to test the safety and feasibility of injecting autologous, isolated, sterile centrifuged NBMC, and IgniteÂ® DBM in the treatment of high risk non union/delayed fractures. Another objective is to turn this procedure to a standard care protocol in our department .</brief_summary>
	<brief_title>Mononucleotide Autologous Stem Cells and Demineralized Bone Matrix in the Treatment of Non Union/Delayed Fractures</brief_title>
	<detailed_description />
	<mesh_term>Fractures, Bone</mesh_term>
	<criteria>1. Ages: 18 to 65 2. Males not involved in active military duty. 3. Femalesnon child bearing potential, or females of childbearing potential who have a negative pregnancy test (hCG urine) within 72 hours of informed consent. 4. Subjects must be available for followup for 1 year. 5"Hard to heal" fracture include the following: A. Fracture of the distal third of the tibial bone B. Segmental or open (II, IIIa an IIIB) fractures of the the tibia or femur diaphysis C.Articular fracture of the lower extremity (distal femur, tibial plateau and tibial pilon fractures) with significant metaphyseal comminution and/or bone loss. 1. Active systemic or local infection. 2. History of malignancy, radiotherapy, or chemotherapy for malignancy (except BCC of the skin) 3. Pathological Fractures. 4. Prior Fracture or Prior operation in the current fracture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>subjects sustaining Non union/delayed fractures and requiring surgical intervention for treatment</keyword>
</DOC>